VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

EHA 2021 | Long-term outcomes with tafasitamab plus lenalidomide for R/R DLBCL

Gilles Salles, MD, PhD, Memorial Sloan Kettering, New York, NY, talks on the use of tafasitamab for the treatment of relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL). Tafasitamab is a monoclonal antibody therapy targeted against CD19 and is used in combination with lenalidomide. Prof. Salles comments on the possibility of curing patients with DLBCL using this therapeutic combination. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter